Navigation Links
Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies

- Combination Therapy Significantly Decreased Tumor Blood Vessel Density and Serum PSA Levels in Prostate Tumors -

LOS ANGELES and TUSTIN, Calif., April 17, 2007 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that preclinical data presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) confirms that a mouse equivalent to Peregrine's novel monoclonal antibody bavituximab given in combination with docetaxel decreased the growth of common forms of prostate cancer significantly more than either agent alone. This increase in anti-tumor efficacy was achieved with no apparent increase in toxicity. Researchers also observed that in one tumor model, the combination significantly decreased the level of serum PSA, a biomarker for prostate cancer, and in both tumor types tested it was more effective in decreasing the density of the microvessels needed to support tumor growth and development.

"This data reaffirms the potential of bavituximab for the treatment of prostate cancer in combination with docetaxel and is particularly timely since we recently completed enrollment in our first human trial of bavituximab in combination with anti-cancer agents including docetaxel," said Steven W. King, president and CEO of Peregrine. "We look forward to assessing further bavituximab's anti-cancer potential in our ongoing clinical trials, as well as in new combination therapy clinical studies we will be initiating later this year."

In this study, the anti-phosphatidylserine (anti-PS) monoclonal antibody 2aG4 (a mouse equivalent antibody to bavituximab) was administered to male mice that had been injected with common forms of hormone dependent and hormone independent tumor cells. Docetaxel and 2aG4 alone
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:12/19/2014)... CHAPEL HILL, N.C. , Dec. 19, 2014 ... how to optimize a product,s web presence to ... critical. Brand websites, in particular, must meet the ... in regulations and culture. According ... LLC, more than half of the participating companies ...
(Date:12/19/2014)...  Monarch America Inc. (OTCQB: CANK) ("Monarch America" or ... provide this review of the Company,s recent achievements and ... "Over this past year, we achieved many of our ... to say that Monarch America is in a stronger ... been," stated Eric Hagen , CEO of Monarch ...
(Date:12/19/2014)... , December 18, 2014 ... software application/module that is used to store, manipulate, ... RIS comprises a patient tracking and scheduling system, ... integration of RIS with HIS and other databases ... patient registration and patient scheduling, patient list management, ...
Breaking Medicine Technology:Building a Best-in-Class Pharma Global Brand Website 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3
... 2 MedAvante, Inc., the leader in centralized evaluation of central nervous ... Service for trials assessing Alzheimer,s Disease. Its CQC Services are already in use ... in the United States , Europe , Asia , ... , , ...
... HARBIN, China , June 2 /PRNewswire-Asia-FirstCall/ ... a,developer, manufacturer and distributor of botanical products,bio-pharmaceuticals and traditional Chinese ... a conference call at 9:00 a.m. Eastern Time ... for the second quarter of its,fiscal year 2010, ended ...
Cached Medicine Technology:MedAvante Launches Service to Boost Reliability of Assessments to Reduce Risk of Failed Alzheimer's Disease Trials 2MedAvante Launches Service to Boost Reliability of Assessments to Reduce Risk of Failed Alzheimer's Disease Trials 3Renhuang Schedules Conference Call to Discuss FY 2010 Second Quarter Results 2Renhuang Schedules Conference Call to Discuss FY 2010 Second Quarter Results 3
(Date:12/21/2014)... Thompson HealthDay Reporter FRIDAY, ... e-cigarettes less addictive than traditional cigarettes, new research finds. ... did regular cigarettes, thousands of ex-smokers said they have fewer ... over their need to smoke, researchers reported. ... less for e-cig use than for tobacco use," said lead ...
(Date:12/21/2014)... AlignLife of Norton Shores is spreading ... same time helping people get their health back. Mission ... to serving those persons in Muskegon County who are unable ... quality of life. Dr. Michael Rykse wanted to do a ... community and he knew he found that when he heard ...
(Date:12/21/2014)... Over the past 39 years, NES Health ... emergency departments across the nation, from quality of medical ... into an innovative suite of tools, systems, and programs ... the patient experience. , NES Health, a leading ... services for hospitals, announced the development and launch of ...
(Date:12/21/2014)... 21, 2014 As testosterone therapy ... attacks, stroke and blood clots from using testosterone products ... new study shows that the male hormone testosterone may ... a study published in the Proceedings of the National ... examined a group of male rats with naturally occurring ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Concept Plus, LLC. ... engineering firm headquartered in Fairfax, VA., today announced it ... its Fast 50 list, which ranks the fastest growing government ... from 2009 to 2013. , This is the first year ... it ranked # 20 with a 95.92% compound annual growth ...
Breaking Medicine News(10 mins):Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Concept Plus, LLC. Named One of Washington Technology’s Fast 50 2
... volunteers, researchers say , TUESDAY, May 11 (HealthDay News) -- ... German researchers tested pain responses in 24 healthy volunteers and ... years ago, increased pain thresholds by up to 50 percent. ... (contralateral) leg. , The study also found that two types ...
... can remain, and heart risks fall , TUESDAY, May 11 ... Close Encounters of the Third Kind was in theaters ... was the year Lawrence Golding, now 81, a professor of ... no-frills, boot-camp-style exercise class for men, held weekdays at lunchtime ...
... ... , ... 11, 2010 -- Richard Marbes, Chairman of the Disabled American Veterans (DAV) Charitable Services Trust ... pleased to advise that favorable consideration was given to the funding request for USA Cares ...
... ... take when facing a personal problem or needing personal advice? What would others do if ... is to serve as a personal advice device to help people learn what others in their ... ...
... ... current and future market trends, convergence, and strategic partnerships from a panel representing different sectors ... ... Industry presentation on Thursday, May 27 at 8:00am in Room 33 of the Donald E. ...
... ... winning products to parents everywhere. , ... (PRWEB) May 11, 2010 -- Companies that submitted products for testing by PTPA Media ... Summer 2010 are here and they’re smart, fun, innovative, and so cool they’re actually hot! ...
Cached Medicine News:Health News:With Long-Term Exercise, Being 80 Is Just a Number 2Health News:With Long-Term Exercise, Being 80 Is Just a Number 3Health News:Disabled American Veterans Charitable Services Trust Supports OIF/OEF Veterans Battling PTSD 2Health News:Quilmach LLC Announces the Introduction of QUILMACH.COM, the first Community Based Personal Advice Device on the Web 2Health News:Quilmach LLC Announces the Introduction of QUILMACH.COM, the first Community Based Personal Advice Device on the Web 3Health News:PSA-TEC to Present State of the Industry Panel Discussion 2Health News:Parent Tested Parent Approved Media Announces their Winning Products for the Summer 2010 Campaign 2
The ReSeeVit Slit Lamp System is an easy-to-use digital video imaging system that captures anterior segment and retinal images for documentation, diagnosis and patient education. The package includes...
... slit lamp is a ... that is designed with ... and has standard 10X ... design provides increased optical ...
... is designed to for use with digital ... offers the popular horizontal style light source. ... family of slit lamps that offers the ... clear, crisp digital images in the most ...
... The first slit lamp truly designed ... for digital video imaging. No other slit ... features of this exceptional product. The ReSeeVit ... product on the market to allow capture ...
Medicine Products: